Federated Hermes
CRSP icon

Federated Hermes’s CRISPR Therapeutics CRSP Stock Holding History

Federated Hermes’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.23M Buy
22,558
+11,785
+109% +$621K ﹤0.01% 1108
2026
Q1 		$512K Sell
10,773
-158
-1% -$8.33K ﹤0.01% 1285
2025
Q4 		$573K Sell
10,931
-11,614
-52% -$696K ﹤0.01% 1269
2025
Q3 		$1.46M Buy
22,545
+9,928
+79% +$570K ﹤0.01% 1028
2025
Q2 		$614K Buy
+12,617
New +$488K ﹤0.01% 1285
2024
Q4 		– Sell
-447,606
Closed -$21M – 2098
2024
Q3 		$21M Hold
447,606
– – 0.05% 409
2024
Q2 		$24.2M Hold
447,606
– – 0.06% 363
2024
Q1 		$30.5M Sell
447,606
-60,494
-12% -$4.33M 0.07% 328
2023
Q4 		$31.8M Hold
508,100
– – 0.08% 282
2023
Q3 		$23.1M Sell
508,100
-658
-0.1% -$34K 0.06% 331
2023
Q2 		$28.6M Hold
508,758
– – 0.07% 309
2023
Q1 		$23M Hold
508,758
– – 0.06% 352
2022
Q4 		$20.7M Hold
508,758
– – 0.06% 376
2022
Q3 		$33.2M Sell
508,758
-72,160
-12% -$5.23M 0.1% 262
2022
Q2 		$35.3M Hold
580,918
– – 0.1% 260
2022
Q1 		$36.5M Hold
580,918
– – 0.08% 293
2021
Q4 		$44M Hold
580,918
– – 0.08% 299
2021
Q3 		$65M Hold
580,918
– – 0.12% 229
2021
Q2 		$94M Sell
580,918
-5,900
-1% -$718K 0.18% 160
2021
Q1 		$71.5M Sell
586,818
-50,282
-8% -$7.59M 0.14% 196
2020
Q4 		$97.5M Sell
637,100
-131,150
-17% -$15.5M 0.2% 129
2020
Q3 		$64.3M Sell
768,250
-309,750
-29% -$27.5M 0.15% 160
2020
Q2 		$79.2M Hold
1,078,000
– – 0.2% 125
2020
Q1 		$45.7M Sell
1,078,000
-183,700
-15% -$9.49M 0.13% 171
2019
Q4 		$76.8M Buy
1,261,700
+400,037
+46% +$21.8M 0.17% 143
2019
Q3 		$35.3M Buy
861,663
+30,000
+4% +$1.43M 0.09% 242
2019
Q2 		$39.2M Buy
831,663
+67,400
+9% +$2.69M 0.1% 232
2019
Q1 		$27.3M Hold
764,263
– – 0.07% 279
2018
Q4 		$21.8M Hold
764,263
– – 0.06% 303
2018
Q3 		$33.9M Buy
764,263
+132,863
+21% +$6.96M 0.08% 254
2018
Q2 		$37.1M Buy
+631,400
New +$36M 0.11% 164

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Federated Hermes's CRSP Position: Q2 2026 in Review

Federated Hermes increased its CRISPR Therapeutics (CRSP) stake by 109% in Q2 2026, buying an estimated $621K and bringing the position to 22,558 shares worth $1.23M. The position accounts for ﹤0.01% of the portfolio, ranked #1108.

Federated Hermes first reported a position in CRSP in Q2 2018 and has held it in 31 quarters since. The position peaked at $97.5M in Q4 2020. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Federated Hermes held 22,558 shares of CRISPR Therapeutics worth $1.23M as of Q2 2026.
  • Federated Hermes bought 11,785 CRISPR Therapeutics shares in Q2 2026, an estimated $621K.
  • CRISPR Therapeutics made up ﹤0.01% of Federated Hermes's portfolio in Q2 2026, its #1108 holding.
  • Federated Hermes first reported a position in CRISPR Therapeutics in Q2 2018 and has held it in 31 quarters since.
  • Federated Hermes's CRISPR Therapeutics position peaked at $97.5M in Q4 2020.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.